Subscribe To

Price Alert Latest News Economic Calendar News

TARS / 7 Biotech Stocks to Buy With Key Catalysts for April

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belonging to the sector seeing some of these make-or-break catalysts. Read More

Demo Live Account See Partner Details

Content Topics

Biotech

Stocks

With

Catalysts

April

Stock

TARS

Posted: Apr 5 2022, 06:59

Author Name: InvestorPlace

TARS News

By GlobeNewsWire
November 1, 2023

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply prov

By Seeking Alpha
September 4, 2023

Tarsus Pharmaceuticals: Worthy Of A Small Bet

Tarsus Pharmaceuticals has received FDA approval for its lotilaner ophthalmic solution for the treatment of Demodex blepharitis. The company just laun

By The Motley Fool
July 20, 2023

Why Shares of Tarsus Pharmaceuticals Are Up Thursday

Tarsus specializes in treating eye and skin disorders. The company is still in the clinical stage but has several late-stage pipeline candidates.

By Zacks Investment Research
July 20, 2023

Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains?

Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimat

By GlobeNewsWire
June 5, 2023

Tarsus to Present at the Jefferies Global Healthcare Conference

IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply prov

By Zacks Investment Research
April 18, 2023

Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock?

Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimat

By Seeking Alpha
January 24, 2023

Tarsus Pharma: Excellent Data, Nice Execution, Unclear Market Potential

Tarsus ran two pivotal trials in an eye indication. Data was excellent and shows that TP-03 will help patients.

By Zacks Investment Research
January 24, 2023

Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength?

Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnin

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.